A longitudinal study of biochemical variables in women at risk of preeclampsia

2002 ◽  
Vol 187 (1) ◽  
pp. 127-136 ◽  
Author(s):  
Lucy C. Chappell ◽  
Paul T. Seed ◽  
Annette Briley ◽  
Frank J. Kelly ◽  
Beverley J. Hunt ◽  
...  
Author(s):  
Cahya Tri Purnami ◽  
◽  
Suharyo Hadisaputro ◽  
Lutfan Lazuardi ◽  
Syarief Thaufik H ◽  
...  

2015 ◽  
Vol 39 (6) ◽  
pp. 530
Author(s):  
Jean-Patrice Baillargeon ◽  
Marie-Claude Battista ◽  
David H. Geller ◽  
Soren Harnois-Leblanc

2002 ◽  
Vol 187 (3) ◽  
pp. 777-784 ◽  
Author(s):  
Lucy C. Chappell ◽  
Paul T. Seed ◽  
CStat ◽  
Frank J. Kelly ◽  
Annette Briley ◽  
...  

2019 ◽  
Vol 43 (1) ◽  
pp. 17-27 ◽  
Author(s):  
Isotta Landi ◽  
Michele Giannotti ◽  
Paola Venuti ◽  
Simona Falco

1998 ◽  
Vol 79 (06) ◽  
pp. 1092-1095 ◽  
Author(s):  
Luca Valsecchi ◽  
Alfonso Fausto ◽  
Danielle Gozin ◽  
Silvana Vigano’ D’Angelo ◽  
Omid Safa ◽  
...  

SummaryIn a prospective longitudinal study, 130 primigravidae at risk for preeclampsia were examined and plasma sampling performed in 45 of them. Plasma thrombomodulin (pTM) was sequentially measured at weeks 12, 24 and 32 of gestation and after delivery in 20 primigravidae who developed either mild preeclampsia (n = 8) or gestational hyper-tension (n = 12) between weeks 32 and 39 of gestation and in 25 (age-matched) primigravidae who had uneventful pregnancies. pTM elevations were not observed until week 32 in uneventful pregnancies, but were present by week 24 (p = 0.002) in patients who later developed hypertensive complications. A net individual pTM increase ≥4.2 ng/ml between weeks 12 and 24 (more than 8 times that of normotensive primigravidae) and/or pTM level ≥47.5 ng/ml at week 32 predicted the development of hypertensive complications with 80% accuracy. Serial pTM determinations can be useful to select pregnancies who may benefit from early pharmacological intervention.


2018 ◽  
Vol 2018 ◽  
pp. 1-9 ◽  
Author(s):  
J. Mayrink ◽  
M. L. Costa ◽  
J. G. Cecatti

Preeclampsia currently remains one of the leading causes of death and severe maternal morbidity. Although its prevalence is still underestimated in some places due to underreporting, preeclampsia is a disease that health professionals need to know how to deal with and take action. For this reason, the studies about the theme remain along with the advances in their understanding that often implies improvement and change of concepts and conducts. The complexity of its etiology is a challenge and requires further studies for its full understanding. Apparently, poor adaptation of the maternal organism to the conceptus, marked by the nonoccurrence of changes in the uterine spiral arteries, determines a series of systemic repercussions that compound the various forms of preeclampsia presentation. In recent years, the use of acetylsalicylic acid to prevent cases of early onset of the disease has been consolidated and, alongside, studies have advanced the development of accessible and effective methods of identifying women at risk of preeclampsia. The aim of this review is to discuss updates on the occurrence, concept, pathophysiology, repercussion, prevention, and prediction of preeclampsia.


2014 ◽  
Vol 7 (3) ◽  
pp. 232-249 ◽  
Author(s):  
Amanda C. Miller ◽  
Douglas Fuchs ◽  
Lynn S. Fuchs ◽  
Donald Compton ◽  
Devin Kearns ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document